A sub-analysis of data from Dendreon Pharmaceuticals’ PROCEED registry comparing overall survival (OS) in African American (AA) and Caucasian (CAU) men with metastatic castrate-resistant prostate cancer (mCRPC) revealed that Provenge (sipuleucel-T) extended the OS of AA men.
The multi-centre, open-label, observational registry PROCEED (NCT01306890) enrolled 1,976 patients with advanced prostate cancer.
Of the total population, 1,902 subjects were given Provenge between 2011 and 2014 in everyday treatment settings.
Provenge is a FDA-approved immunotherapy made from a patient’s own immune cells for the treatment of prostate cancer.
The study noted that PSA-matched AA men demonstrated a median OS of over 4.5 years when compared to CAU men with a baseline PSA less than or equal to the median (29.48 ng/mL).
An improvement of 20.9 months and a 48% relative risk reduction in death was observed in CAU men whose OS rates were noted to be 2.7 years.
Dendreon Pharmaceuticals chief medical officer Bruce Brown said: “These findings add to the growing body of published clinical evidence that Provenge extends life in men with mCRPC and underscore its added effectiveness in African American men.”
“No other prostate cancer treatment has shown this level of added benefit in African American men with mCRPC, so these findings are exciting.”
Prostate cancer is the most frequently occurring non-cutaneous cancer among men in the US. It is considered the second leading cause of cancer-related deaths. AA men are said to have the highest prostate cancer incidence rate.
In May 2018, Dendreon announced its plans to conduct the new ProVent clinical trial to examine the effectiveness of Provenge in preventing disease progression in men with prostate cancer on active surveillance (AS).